Price War and Muscle Risk Define New Era of Obesity Drug Access

The landscape of obesity treatment is undergoing a transformation as popular GLP-1 drugs, originally developed for diabetes, become more accessible and affordable. On the financial front, an agreement between the Trump administration and two major drugmakers, Eli Lilly and Novo Nordisk, is set to drastically reduce the cost of these medications for millions of Americans enrolled in Medicare and Medicaid, as well as for cash buyers. While current injectable versions can retail for up to 1,000permonth,oralversionsbeingdevelopedareexpectedtorangefrom∗∗149 to $350 a month** if approved by the FDA, potentially expanding access significantly.

However, experts stress that increased access must be paired with clinical clarity and a comprehensive treatment strategy, as obesity is a chronic, multifactorial disease, not merely a failure of willpower. Lia Gass Rodriguez, MD, Chief Medical Officer at CVS Healthspire Payor Solutions, noted that despite the clinical benefits, these drugs remain "egregiously priced," which creates access challenges. Currently, only 29% of commercial health plan members have coverage for GLP-1s for obesity.

A key concern raised by University of Virginia associate professor Siddhartha Angadi is that weight loss is not synonymous with good health. Angadi, a cardiovascular exercise physiologist, emphasizes that there is limited information regarding the long-term effects of taking medications like semaglutide and tirzepatide. Furthermore, data indicates that the weight often returns once patients discontinue the medication, underscoring the need to view these drugs as "for life".

A critical finding in recent research co-written by Angadi highlights the risk to muscle mass. Approximately 40% of the weight people lose when using drugs like Wegovy or Zepbound comes from fat-free mass (everything in the body that is not fat), and up to 50% of that non-fat mass can be muscle. This raises serious questions about long-term issues related to aging, frailty, and fitness. Angadi noted the importance of physical activity and strength training, stating that an individual who is obese but fit has half the risk of death compared to someone who is normal weight but unfit.

This clinical complexity demands that pharmacotherapy be paired with structured lifestyle interventions. Dr. Rodriguez made a strong case for this integrated approach, citing CVS’ own program data. Individuals who combine medication with support, such as registered dietitian-led medical nutrition therapy, have shown remarkable results, with some achieving weight loss exceeding 18%. Critically, those who discontinued the drug but remained engaged with dieticians for at least six months retained 90% of the weight they lost.

Leaders are urged to view GLP-1s not as "silver bullets," but as one vital component of a broader, evidence-based strategy that prioritizes sustained behavior change and clinical integration.

---

🔖 Sources

GLP-1s and the future of obesity care: 4 takeaways on coverage, cost + clinical clarity

As GLP-1 drugs go mainstream, this expert says health is more than a number on a scale

---

Keywords: Obesity Drug Access

 Obesity Drug Access

---